Jersey could approve medical cannabis farm after its first clinic established

3rd November 2021

Grouville on the isle of Jersey could soon be welcoming a new medical cannabis farm if a recent planning application is approved. The news comes after the announcement of the island’s very first medical cannabis clinic last year.

According to the Jersey Evening Post, a charity shop and a care home would also be built alongside the proposed cannabis farm on a site next to the Holme Grown farm shop in Grouville.

The planning application will be submitted by GroVida Jersey Ltd to produce cannabis-based medical products to export to the UK and Europe.

The company, the JEP reports, has applied for a licence to cultivate cannabis in several facilities on the island.

Holme Grown managing director Stanley Payn said: “It’s important to note that this is only a proposal at the moment, but it is exciting to combine three projects that will benefit the future economy of the Island.

“A new care home facility in the east is much needed, together with a Hospice fundraising outlet that will complement the site for the benefit of the eastern community.

“The parish of Grouville is well aware of the potential of the scheme, which will hopefully make active a site that was [previously] a hub of activity.”

Last year, Canex reported that Jersey would welcome its first medical cannabis clinic.

The Medicann clinic is now open on Jersey, giving patients on the island more convenient access to medical cannabis products. Prior to the opening of the clinic, residents were only able to access cannabis medicines through video consultations with – or by travelling to – clinics on the UK mainland.

The National Institute of Health and Care Excellence (NICE) has, to date, only recommended the use of medical cannabis for an extremely limited list of conditions – namely, treatment-resistant epilepsy, spasticity associated with multiple sclerosis, and as an add-on therapy for intractable nausea and vomiting.

However, specialist clinicians are able to prescribe cannabis products for a wider variety of conditions given there is reasonable evidence for their potential to reduce symptoms.

Related Stories